Pulmonary Vein Isolation with a New Multipolar Irrigated Radiofrequency Ablation Catheter (nMARQ™): Feasibility, Acute and Short‐Term Efficacy, Safety, and Impact on Postablation Silent Cerebral Ischemia. (14th September 2014)

• Record Type: Journal Article
• Authors: SCAGLIONE, MARCO; CAPONI, DOMENICO; ANSELMINO, MATTEO; CLEMENTE, FRANCESCA DI; BLANDINO, ALESSANDRO; FERRARIS, FEDERICO; DONNA, PAOLO DI; EBRILLE, ELISA; HALIMI, FRANCK; LECLERCQ, JEAN F.; IUNCO, COSTANZA; VAUDAGNA, CARLOEUGENIO; CESARANI, FEDERICO; GAITA, FIORENZO
• Is Part Of: Journal of cardiovascular electrophysiology. Volume 25:Number 12(2014:Dec.)
• Page Start: 1299
• Page End: 1305
• Publication Date: 2014-09-14
• Subjects: Blood vessels -- Physiology -- Periodicals; Electrophysiology -- Periodicals; Heart -- Physiology -- Periodicals; 612.1
• DOI: 10.1111/jce.12500
• Languages: English
• ISSNs: 1045-3873

Abstract

<abstract abstract-type="main"> <title>PVI with nMARQ™</title> <sec id="jce12500-sec-0010" sec-type="section"> <title>Background</title> <p>Simultaneous multipolar ablation catheters have been proposed to simplify pulmonary vein isolation (PVI) in paroxysmal atrial fibrillation (AF). Recently, a new multipolar irrigated radiofrequency (RF) ablation catheter (nMARQ™, Biosense Webster Inc., Diamond Bar, CA, USA) combining both 3‐dimensional electroanatomic mapping and multipolar open‐irrigated ablation capability has been developed. Aim of our study was to assess feasibility, acute and short‐term success and safety of PVI by the use of this new technology with particular regard to the incidence of postablation silent cerebral ischemia (SCI).</p> </sec> <sec id="jce12500-sec-0020" sec-type="section"> <title>Methods and Results</title> <p>Twenty‐five patients (76% males; age 57 ± 13 years) with paroxysmal AF underwent PVI using the nMARQ™ catheter. PVI, confirmed by Lasso catheter mapping, was achieved in 100 out of 102 pulmonary veins (98%) identified, and final PVI was obtained in 24 out of 25 (96%) patients. The overall concordance between Lasso and nMARQ™ signals in demonstrating PVI was 78%. No major procedural complications occurred and no patient suffered SCI, on the basis of cerebral magnetic resonance imaging performed before and after the procedure. Following a 6‐month follow‐up, 17/25 (68%) patients remained free from AF without antiarrhythmic drugs.</p> </sec> <sec id="jce12500-sec-0030" sec-type="section"> <title>Conclusions</title> <p>In our preliminary experience, PVI with nMARQ™ catheter appears to be feasible and safe, without incidence of SCI. Long‐term clinical efficacy has to be evaluated in further studies.</p> </sec> </abstract>